Raf-mek-erk pathway inhibitors to treat cancer

Details Raf-mek-erk pathway inhibitors to treat cancer Raf-mek-erk pathway inhibitors to treat cancer

A - Human Necessities

61

K

A61K 31/4412 (2006.01) A61K 31/00 (2006.01) A61K 31/166 (2006.01) A61K 31/44 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2466762

Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.

L'invention concerne des matériaux et des méthodes permettant de traiter certains cancers, de préférence des cancers résultant de la régulation ascendante de la voie RAF-MEK-ERK, et plus particulièrement la leucémie myélogène chronique, ce cancer résistant de préférence à l'agent inhibiteur de la Ber-Abl tyrosine kinase, l'imatinib.

Affiliated with

Also associated with

Rating

Raf-mek-erk pathway inhibitors to treat cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Raf-mek-erk pathway inhibitors to treat cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Raf-mek-erk pathway inhibitors to treat cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1408627